Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial-Reference-Cited by-同舟云学术

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial

Published:2017-07 Issue:10089 Volume:390 Page:50-61
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Heier Jeffrey S,Kherani Saleema,Desai Shilpa,Dugel Pravin,Kaushal Shalesh,Cheng Seng H,Delacono Cheryl,Purvis Annie,Richards Susan,Le-Halpere Annaig,Connelly John,Wadsworth Samuel C,Varona Rafael,Buggage Ronald,Scaria Abraham,Campochiaro Peter A

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Engl J Med,2006

2. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration;Singer;Ophthalmology,2012

3. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two year results;Martin;Ophthalmology,2012

4. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration;Honda;Gene Ther,2000

5. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization;Gehlbach;Gene Ther,2003

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in ophthalmic therapeutic delivery: A comprehensive overview of present and future directions;Survey of Ophthalmology;2024-11

2. Gene and cell therapy for age-related macular degeneration: A review;Survey of Ophthalmology;2024-09

3. Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications;Angiogenesis;2024-08-29

4. Current developments of gene therapy in human diseases;MedComm;2024-08-16

5. The AAV2.7m8 capsid packages a higher degree of heterogeneous vector genomes than AAV2;Gene Therapy;2024-08-12